7 June 2019

MSD Animal Health Receives Marketing Authorization from European Authorities for BOVILIS® INtranasal RSP™ Live Vaccine for Cattle

MADISON, N.J., June 7, 2019 MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, today announced that European Authorities have granted marketing authorization for the veterinary medicinal product BOVILIS® INtranasal RSP™ Live. This intranasal, live vaccine can be used in calves as young as one week of age for active immunization and to reduce clinical signs of Bovine Respiratory Disease (BRD) and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (PI3V).

The BOVILIS® INtranasal RSP™ Live vaccine is a farm-friendly, nasal suspension product with an innovative intranasal spray technology. It is the only European Union-licensed vaccine against BRD that can be administered one week after a calf’s birth. Early age protection can prevent pneumonia and impact a calf’s productive future.

BOVILIS® INtranasal RSP™ Live is registered through the EU decentralized procedure. European Union countries are currently finalizing their national registrations following the positive outcomes of this assessment. Detailed product conditions are described in the Summary of Product Characteristics (SPC), and will be translated in all European Union languages for publishing by individual regulatory authorities.i

MSD Animal Health Ruminants
With the broad portfolio of BOVILIS® vaccines, MSD Animal Health supports the most complete, preventive health solutions, support services and continuous education. The company’s “Science of Prevention” program, a preventative approach to disease across the entire lifecycle, aims to help educate veterinarians and producers on how to implement prevention methods before the animal is born, when it is growing up, and during production in adulthood to effectively improve animal health, well-being and productivity. The three pillars of the “Science of Prevention” are disease avoidance, achieved through good animal husbandry, stress-free housing, vaccination, hygiene and nutrition; prompt diagnosis and treatment, aimed at preventing the spread of disease, disease severity and complications; and the health restoration of affected animals.

Vaccines play an important role in protecting animal and public health. Timely and effective vaccination reduces the incidence and severity of disease, enabling efficient production of food animals. The health and well-being of animals is the first and foremost priority of MSD Animal Health.

About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn and Twitter.

iPlease see the first European prescribing information for BOVILIS® INtranasal RSP™ Live on http://www.ircp.anmv.anses.fr/fiche.aspx?NomMedicament=BOVILIS+INTRANASAL+RSP+LIVE